The results showed that the promoter methylation was associated with gender, tumor stage, and TP53 mutation status in LUAD patients (Figures 5(b), 5(d), and 5(e)); however, there was no correlation between promoter methylation and LUAD patients who aged 21-40 or 81-100 and patients of African ethnicity (Figures 5(c) and 5(f)). The gene discussed is TP53; the disease is neoplasm.